Colin Dalton - Chairman & Management Consultant
Colin joined Coalesce in 2015 in an advisory associate role, bringing a wealth of experience in business development, realising value, and negotiation, in the pharmaceutical, vaccine, biotech and medtech industries.
With a BTech from Brunel and a PhD from Leicester University, he started out as a fermentation scientist at BP Co Ltd. He went on to positions at PA Consulting, British Sugar plc, and Quandrant Holdings Cambridge Limited before becoming Director of Business Development at GSK Biologicals S.A., managing a group responsible for licensing new vaccines and technologies, collaborations and alliances.
Since then, other directorships and board positions have included: Observer on the Board of Profibrix B.V., a novel haemostatic product company; Company Director of Innovata PLC; Innovata Biomed Limited; Quadrant Technologies Limited and Quadrant Healthcare Limited; and Director of IP and Corporate Affairs for Vectura Group plc.
He is currently Company Director of Margarite Limited, a UK consulting company, non-executive director of Imcyse SA, and sits on the Supervisory Board of the Center for Drug Design and Discovery (CD3).
His favourite woodworking tool is a fishtail carving chisel, sweep #4.